Eisai Co. Ltd (EII F) stock market data APIs
€26.6012
0(0%)
as of November 28, 2025
Try our APIs with
free plan!
Eisai Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. The company offers Dayvigo, an orexin receptor antagonist for the treatment of insomnia; LEQEMBI, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody for Alzheimer's disease; Lenvima, an orally available multiple receptor tyrosine kinase inhibitor for the treatment of thyroid cancer and hepatocellular carcinoma, thymic carcinoma, renal cell carcinoma, and endometrial carcinoma; Fycompa, an anti-epileptic agent for primary generalized tonic-clonic seizures; and Halaven, a microtubule dynamics inhibitor for breast cancer and liposarcoma. It operates in Japan, China, the Americas, Europe, the Middle East, Africa, and East Asia Global South. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Prev. Close
26.6012
Open
26.6012
High
26.6012
Low
26.6012
52 wk Range
-51.13-30.9057
Market Cap
7 648 M
P/E Ratio
27.5258
Shares Outstanding
282 M
Revenue
804 390 M
Dividends (Yield)
0.0363
Beta
-0.247
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eisai Co. Ltd data using free add-ons & libraries
Get Eisai Co. Ltd Fundamental Data
Eisai Co. Ltd Fundamental data includes:
- Net Revenue: 804 390 M
- EBITDA: 93 028 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: 30.06
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eisai Co. Ltd News
New
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
Biogen Inc. If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease ...
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
Biogen Inc.; Eisai Co., Ltd. LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients...
Wall Street Gains, Fed Outlook Lift Asian Stock Markets
Asian stock markets churned higher Tuesday on overnight Wall Street cues, and on hopes for a rate cu PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Novo Dives After Weight-Loss Pill Fails In Alzheimer's Disease; Biogen Jumps
Novo Nordisk stock plummeted Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's disease in two big studies. Continue Reading View Comments
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
